Accelerating Clinical Trials in the European Union (ACT-EU)
The Multistakeholder Platform (MSP) and the position of the European Industrial Pharmacists Group (EIPG) by Rebecca Rebecca Stanbrook…
Reform of pharma legislation: the debate on regulatory data protection
by Giuliana Miglierini As the definition of the final contents of many new pieces of the overall revision…
EMA’s reflection paper on AI in the pharmaceutical lifecycle
by Giuliana Miglierini The rapidly evolving role of artificial intelligence (AI) and its possible application in the pharmaceutical…
The new MHRA’s framework for clinical studies
By Giuliana Miglierini The repositioning of the United Kingdom as a global leader for clinical development of medicinal…
ICMRA report on best practices against antimicrobial resistance
by Giuliana Miglierini Antimicrobial resistance (AMR) is the consequence of mutations that allow microbes to survive pharmacological treatment.…
ACT EU’s Workplan 2022-2026
by Giuliana Miglierini The implementation phase of the Accelerating Clinical Trials in the EU (ACT EU) initiative, launched…